Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Mauna Kea Technologies (OTC: MKEAF).

Full DD Report for MKEAF

You must become a subscriber to view this report.


Recent News from (OTC: MKEAF)

Cellvizio® Obtains Positive Assessment from the Korean National Evidence-based healthcare Collaborating Agency (NECA)
New Health Technology Assessment (nHTA) Committee recognizes confocal laser endomicroscopy as “safe and effective technology in application for esophagus, stomach, bile duct ” New Health Technology status enables specific reimbursement codes for Cellvizio® proc...
Source: Business Wire
Date: March, 15 2018 13:11
VIDEO: Mauna Kea Technologies' CEO, Sacha Loiseau, Ph.D., Featured in OTCQX Video Series
NEW YORK , Jan. 22, 2018 /PRNewswire/ --  Mauna Kea Technologies (OTCQX: MKEAY; MKEAF) CEO Sacha Loiseau was interviewed by OTC Markets Group (OTCQX: OTCM) in its prominent OTCQX® Video Series. The series features one-on-one interviews with senior executives of OTCQX compan...
Source: PR Newswire
Date: January, 22 2018 07:00
Mauna Kea Technologies reports Q3 results
Mauna Kea Technologies ( OTCQX:MKEAF ): Q3 Revenue of €1.85M (-11.9% Y/Y) Press Release More news on: Mauna Kea TechnologiesO, Earnings news and commentary, Consumer stocks news, ,
Source: SeekingAlpha
Date: October, 19 2017 12:31
Mauna Kea Technologies reports 1H results
Mauna Kea Technologies ( OTCQX:MKEAF ): 1H Net loss of €5.79M. More news on: Mauna Kea TechnologiesO, Earnings news and commentary, Consumer stocks news, , Read more ...
Source: SeekingAlpha
Date: September, 20 2017 12:02

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-14N/A3.40N/AN/A0
2018-12-13N/A3.40N/AN/A0
2018-12-12N/A3.40N/AN/A0
2018-12-11N/A3.40N/AN/A0
2018-12-10N/A3.40N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-01-185050100.0000Short
2017-11-16200200100.0000Short
2017-10-25716716100.0000Short
2017-07-1710070014.2857Cover
2017-07-05500500100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on MKEAF.


About Mauna Kea Technologies (OTC: MKEAF)

Logo for Mauna Kea Technologies (OTC: MKEAF)

Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer thanks to real time in vivo microscopic visualization. The Company s flagship product, Cellvizio, has received clearance to sell a wide range of applications in more than countries, including the United States, Europe, Japan, China, Canada, Brazil and Mexico. More than systems around the world and investigators have generated more than publications on clinical applications of endomicroscopy.

 

 

 

Current Management

  • Sacha Loiseau / CEO, Founder
    • Sacha founded Mauna Kea Technologies in May and has been the CEO ever since. A coinventor of the probebased Confocal Laser Endomicroscopy technology, he piloted the development of the Cellvizio product line, raising over million with private investors until taking the company public in July on the NYSE Euronext Paris stock exchange. Mauna Kea s IPO enabled a capital raise of . million with new investors only and was the largest healthcare IPO in Europe in . In , Sacha was named the colead of France s Reindustrialization Plan for Medical Devices by the French President. Sacha sits on the PostPlanning Board at Ecole Polytechnique and was instrumental in the foundation of the French MedTech association InnoTechMed France. Sacha is a former board member of Sinequa, an enterprise search company. Sacha started his career at the National Center for Space Studies CNES in Toulouse and at the Paris Observatory, then joined NASA s Jet Propulsion Laboratory JPL in Pasadena, California, as a research scientist. Sacha is a graduate of the cole Polytechnique in Paris and has a Ph.D. in Astrophysics and Optical Instrumentation. Sacha is the author of multiple scientific articles and holds international patents.
  • May Kang Yu / Finance Manager
  • Christopher D. McFadden / Chairman, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
    • Christopher McFadden is the founder of the Canyon Healthcare Partners, an investment fund. Between and , he was a Managing Partner at Health Evolution Partners, an American healthcarefocused private equity fund. Between and , he was Senior Financial Analyst at Goldman, Sachs amp Co. in New York before heading healthcaresector investment activities for Goldman Sachs Americas Special Situations Group AmSSG . Mr. McFadden is also a Trustee for Montefiore Medical Center in New York and the Natural History Museum of the Adirondacks.
  • JeanLuc Boulnois / Independent Director, Audit Committee Member
    • JeanLuc Boulnois is the Executive Chairman of the Board at Microline Surgical, an innovative minimallyinvasive surgical instrument company with which he has been involved for years as an investor and then, from to as CEO, heading a period of uninterrupted growth. He was also CEO of Sometec from to and President and COO of Technomed International from to , two medical technology companies. With French and American dual citizenship, Mr Boulnois has been living in Boston for close to years. He holds a PhD in Aerospace Engineering from Princeton University and an Executive MBA from HEC.
  • Joseph DeVivo / Independent Director, Audit Committee Member
    • Joseph DeVivo has been the CEO of InTouch health since July . Before that, M. DeVivo served as CEO of AngioDynamics since September . Previously, Mr. DeVivo was CEO and President of RITA Medical Systems. Mr. DeVivo most recently served as Global President of Smith amp Nephew Orthopedics. Prior to RITA Medical Systems, Mr. DeVivo served as President, Chief Operating Officer and Director of Computer Motion Incorporation CMI . Mr. DeVivo previously served as Vice President and General Manager of a million division of TYCO International s Healthcare Business, U.S. Surgical/Davis and Geck Sutures. During his nineyear tenure at U.S. Surgical, he held various management positions related to sales and marketing, supervising numerous product launches and implementing new sales and marketing strategies Mr. DeVivo earned his Bachelor of Science degree in Business Administration from the E. Clairborne Robins School of Business at the University of Richmond.
  • Sacha Loiseau / Director
    • Sacha founded Mauna Kea Technologies in May and has been the CEO ever since. A coinventor of the probebased Confocal Laser Endomicroscopy technology, he piloted the development of the Cellvizio product line, raising over million with private investors until taking the company public in July on the NYSE Euronext Paris stock exchange. Mauna Kea s IPO enabled a capital raise of . million with new investors only and was the largest healthcare IPO in Europe in . In , Sacha was named the colead of France s Reindustrialization Plan for Medical Devices by the French President. Sacha sits on the PostPlanning Board at Ecole Polytechnique and was instrumental in the foundation of the French MedTech association InnoTechMed France. Sacha is a former board member of Sinequa, an enterprise search company. Sacha started his career at the National Center for Space Studies CNES in Toulouse and at the Paris Observatory, then joined NASA s Jet Propulsion Laboratory JPL in Pasadena, California, as a research scientist. Sacha is a graduate of the cole Polytechnique in Paris and has a Ph.D. in Astrophysics and Optical Instrumentation. Sacha is the author of multiple scientific articles and holds international patents.
  • Marie Meynadier / Independent Director, Compensation Committee Member, Nominating Committee Member
    • Marie Meynadier is the CEO of EOS Imaging Euronext: EOSI, FR . She began her career at the prestigious Bell Labs, and then steered the management of major development programs in France in the fields of electronics, optics and microelectronics, which led to the creation of several startups. Marie Meynadier is a graduate of Sup Telecom and has a PhD in Physics from cole Normale Suprieure on rue d Ulm, Paris.

Current Share Structure

  • Market Cap: $116,010,660 - 03/16/2018
  • Authorized: 21,029,719 - 05/04/2016
  • Issue and Outstanding: 20,001,838 - 12/31/2016
  • Float: 16,249,410 - 12/31/2016

 


Recent Filings from (OTC: MKEAF)

Semi-Annual Report - 2017 half year financial report
Filing Type: Semi-Annual Report - 2017 half year financial reportFiling Source: OTC Markets
Filing Date: October, 04 2017

 

 


Daily Technical Chart for (OTC: MKEAF)

Daily Technical Chart for (OTC: MKEAF)


Stay tuned for daily updates and more on (OTC: MKEAF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: MKEAF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in MKEAF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of MKEAF and does not buy, sell, or trade any shares of MKEAF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/